Skip to content
lifestyle.ideacrossing.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Santhera Pharmaceuticals Holding AG
Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea
October 23, 2026
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
September 30, 2026
Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus
July 13, 2026
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
July 1, 2026
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea
June 2, 2026
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
May 26, 2026
Santhera Publishes Agenda for its Annual General Meeting
May 23, 2026
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
May 22, 2026
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
May 22, 2026
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
May 22, 2026
1
2
Next Page
→